Medpace Holdings, Inc.

Medpace Holdings, Inc. (MEDP) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The "Sticky" Moat: This isn't just a service; it's a regulatory hostage situation. Once a biotech firm embeds its trial data and FDA protocols with Medpace, switching CROs mid-stream is financial and regulatory suicide. The switching costs are immense, creating a predictable, recurring-style revenue stream.
• Operating Leverage Lollapalooza: Most service businesses scale linearly—more revenue requires proportionally more people. Medpace has defied this. Growing revenue from $0.4B to $2.5B while expanding margins from 3.2% to 17.8% suggests a proprietary operational system that gets more efficient as it grows.
• Purity of Execution: I love a management team that doesn't "buy" growth. The lack of acquisitions is a signal of extreme discipline. They aren't hiding poor organic growth behind accounting tricks or overpriced M&A; they are building a fortress brick by brick.
• Cash Generation: FCF of $0.7B against Net Income of $0.5B tells me the earnings are conservative. The business is printing cash faster than the accountants can report it.
• Attractive Range: This becomes a "no-brainer" if we can secure a significant slice of the business at a price that ignores the current biotech hype and focuses on the long-term cash flow.

🐻 The Bear Case (Charlie inverts)

"Show me where I'll die and I won't go there."

• The Biotech Funding Cliff: Medpace is heavily weighted toward small-to-mid-cap biotech. These companies don't have their own cash; they have VC money. If the venture capital appetite for drug discovery suffers a permanent structural collapse (not just a cycle), Medpace's pipeline evaporates.
• The AI Disruption: The "specialized labor" moat is based on human expertise in regulatory slogs. If Generative AI and LLMs can automate trial design, patient matching, and FDA submission drafting, the "specialized labor" premium vanishes. The business transforms from a high-margin expert to a low-margin commodity software interface.
• Concentration Risk: A pivot in FDA requirements that simplifies clinical trials could commoditize the process, stripping away the "regulatory minefield" that creates their switching costs.
• Most Likely Threat: The Biotech Funding Cliff. It is the single point of failure. If the capital markets stop funding the "dreamers," the "engineers" at Medpace have nothing to build.

💰 Valuation & Margin of Safety

Based on the DCF estimate of $24.4B total value.

• Intrinsic value estimate: $861.01 per share
• 25% margin of safety entry: $645.76 (The "Disciplined" price)
• 50% margin of safety entry: $430.51 (The "Fat Pitch" price)
• Current Status: If the stock is trading near $861, it is fairly valued—a wonderful company at a fair price, but not a "Berkshire" bargain. We require the price to drop toward the $645 mark to compensate for the volatility of the biotech funding environment.

Verdict: WATCH

The business is a high-quality compounding machine with a rare organic growth profile. However, we do not pay retail for excellence. We wait for a biotech sector panic to drive the price toward $645 before committing significant capital.